Literature DB >> 28252282

Reverse Microemulsion-Based Synthesis of (Bis)phosphonate-Metal Materials with Controllable Physical Properties: An Example Using Zoledronic Acid-Calcium Complexes.

Xu Li1, Youssef W Naguib1, Solange Valdes1, Stephanie Hufnagel1, Zhengrong Cui1.   

Abstract

The development of phosphonate-metal materials is tightly related to the advancement in their synthesis methods. Herein, using zoledronic acid (Zol), a bisphosphonate (bioacitve phosphonate with a "P-C-P" structure), and calcium as model molecules, we applied the reverse microemulsion (RM) method to synthesize a series of Zol-Ca complexes. We comprehensively (i) studied the relationship between RM conditions, including the component ratio of RM, cosurfactants, reaction time, reactant concentration, reaction temperature, and the presence of a phospholipid, 1, 2-dioleoyl-sn-glycero-3-phosphate acid (DOPA), and the physical properties of the complexes synthesized (i.e., shape, size, uniformity, monodispersity, and hydrophilicity/hydrophobicity) and (ii) explored the underlying mechanisms. To evaluate the biomedical application potential of the Zol-Ca complexes synthesized, one type of hydrophobic, DOPA-coated spherical Zol-Ca complexes (denoted as Zol-Ca@DOPA) was formulated into a PEGylated lipid-based nanoparticle formulation (i.e., Zol-Ca@bilipid NPs, ∼24 nm in diameter). In a mouse model with orthotopic mammary tumors, the Zol-Ca@bilipid NPs significantly enhanced the distribution of Zol in tumors, as compared to free Zol. It is expected that the RM-based synthesis of (bis)phosphonate-metal materials with controllable physical properties will help expand their applications.

Entities:  

Keywords:  distribtuion in tumor; formation mechanism; macrophages; microemulsion compositions; nanoparticles; reaction conditions

Year:  2017        PMID: 28252282      PMCID: PMC5485920          DOI: 10.1021/acsami.6b15006

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  36 in total

1.  The role of soft colloidal templates in controlling the size and shape of inorganic nanocrystals.

Authors:  Marie-Paule Pileni
Journal:  Nat Mater       Date:  2003-03       Impact factor: 43.841

2.  Shape effects of filaments versus spherical particles in flow and drug delivery.

Authors:  Yan Geng; Paul Dalhaimer; Shenshen Cai; Richard Tsai; Manorama Tewari; Tamara Minko; Dennis E Discher
Journal:  Nat Nanotechnol       Date:  2007-03-25       Impact factor: 39.213

3.  The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo.

Authors:  Xinglu Huang; Linlin Li; Tianlong Liu; Nanjing Hao; Huiyu Liu; Dong Chen; Fangqiong Tang
Journal:  ACS Nano       Date:  2011-06-08       Impact factor: 15.881

4.  Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.

Authors:  G Salzano; M Marra; M Porru; S Zappavigna; A Abbruzzese; M I La Rotonda; C Leonetti; M Caraglia; G De Rosa
Journal:  Int J Pharm       Date:  2010-11-03       Impact factor: 5.875

5.  Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth.

Authors:  G Salzano; S Zappavigna; A Luce; N D'Onofrio; M L Balestrieri; A Grimaldi; S Lusa; D Ingrosso; S Artuso; M Porru; C Leonetti; M Caraglia; G De Rosa
Journal:  J Biomed Nanotechnol       Date:  2016-04       Impact factor: 4.099

6.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Authors:  Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

7.  Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.

Authors:  Lee S Rosen; David Gordon; N Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; Maciej Krzakowski; Marek Pawlicki; Paul De Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John Seaman
Journal:  Cancer       Date:  2004-06-15       Impact factor: 6.860

8.  Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer.

Authors:  Chunbai He; Demin Liu; Wenbin Lin
Journal:  Biomaterials       Date:  2014-10-12       Impact factor: 12.479

9.  Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.

Authors:  Mengmeng Niu; Solange Valdes; Youssef W Naguib; Stephen D Hursting; Zhengrong Cui
Journal:  Mol Pharm       Date:  2016-04-26       Impact factor: 4.939

10.  Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.

Authors:  Joanna Kopecka; Stefania Porto; Sara Lusa; Elena Gazzano; Giuseppina Salzano; Martha Leonor Pinzòn-Daza; Antonio Giordano; Vincenzo Desiderio; Dario Ghigo; Giuseppe De Rosa; Michele Caraglia; Chiara Riganti
Journal:  Oncotarget       Date:  2016-04-12
View more
  4 in total

1.  Aluminum (Oxy)Hydroxide Nanosticks Synthesized in Bicontinuous Reverse Microemulsion Have Potent Vaccine Adjuvant Activity.

Authors:  Xu Li; Stephanie Hufnagel; Haiyue Xu; Solange A Valdes; Sachin G Thakkar; Zhengrong Cui; Hugo Celio
Journal:  ACS Appl Mater Interfaces       Date:  2017-06-29       Impact factor: 9.229

2.  In vivo distribution of zoledronic acid in a bisphosphonate-metal complex-based nanoparticle formulation synthesized by a reverse microemulsion method.

Authors:  Xu Li; Youssef W Naguib; Zhengrong Cui
Journal:  Int J Pharm       Date:  2017-04-26       Impact factor: 5.875

3.  Soft and Condensed Nanoparticles and Nanoformulations for Cancer Drug Delivery and Repurpose.

Authors:  Wen Yang; Hanitrarimalala Veroniaina; Xiaole Qi; Pengyu Chen; Feng Li; Pu Chun Ke
Journal:  Adv Ther (Weinh)       Date:  2019-10-16

4.  Zoledronic Acid-containing Nanoparticles With Minimum Premature Release Show Enhanced Activity Against Extraskeletal Tumor.

Authors:  Xu Li; Solange A Valdes; Riyad F Alzhrani; Stephanie Hufnagel; Stephen D Hursting; Zhengrong Cui
Journal:  ACS Appl Mater Interfaces       Date:  2019-02-11       Impact factor: 9.229

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.